Oncology market to reach $748B by 2035, immuno-oncology $170B by 2032
The global oncology market is projected to grow from $279.98 billion in 2026 to $748.17 billion by 2035, with immuno-oncology expanding from $65.22 billion in 2025 to $170.19 billion by 2032. Gilead Sciences is identified among five leading companies advancing novel cancer therapies in this rapidly growing segment.
1. Oncology Market Growth Projections
Analysts forecast the global oncology market will nearly triple in value, rising from $279.98 billion in 2026 to an estimated $748.17 billion by 2035. The immuno-oncology segment alone is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, reflecting a 14.9% compound annual growth rate.
2. Gilead Sciences Among Top Oncology Innovators
Gilead Sciences is named alongside Exelixis, Lilly, Merck and Oncolytics Biotech as one of five companies leading advancements in targeted and immuno-oncology therapies. While specific Gilead programs are not detailed here, inclusion in this group signals positioning to capitalize on the sector’s projected growth.